SQI Diagnostics Inc. (TSXV: SQD) CEO Andrew Morris describes how his company’s technology permits many different types of diagnostic tests to be performed at the same time using the same biological sample in smaller amounts, resulting in substantial time and money savings. He also outlines the industry validation SQI has received so far, including a few large pharma companies such as Bristol-Myers Squibb, and hints at newsworthy events in the coming year that should be positive for the company’s stock price.
Ubika Research has received compensation from SQI Diagnostics Inc. to provide analyst research coverage.
Except for the historical information presented herein, matters discussed in this document contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.
Ubika Research and smallcappower.com (are both divisions of Ubika Corporation), and are not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this report. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: https://smallcappower.com/disclosure/.
About Ubika Research
Ubika is an investment research and capital market services firm based in Toronto and Vancouver with a proven track record of identifying and launching coverage of high potential small cap stocks at an early stage, thus offering timely market insights. Its specialty is small-cap companies with a market capitalization of <$5 billion.